TD Cowen Maintains Outperform on NeoGenomics, Lowers Price Target to $19

NeoGenomics, Inc. +0.73% Pre

NeoGenomics, Inc.

NEO

13.85

13.85

+0.73%

0.00% Pre

TD Cowen analyst Dan Brennan maintains NeoGenomics (NASDAQ: NEO) with a Outperform and lowers the price target from $22 to $19.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via